Clinical Trial Results:
A Randomised, Phase II, Double-Blind, Double-Dummy, four-period Crossover Efficacy and Safety Comparison of 4-Week Treatment Periods of Blinded Fluticasone (500 μg bid, MDI), Ciclesonide (400 μg qd, MDI), Ciclesonide (800 μg qd, MDI) or placebo in Free Combination with Open-Label Tiotropium (18 μg qd, HandiHaler®) and Salmeterol (50 μg bid, Diskus®) in Patients with COPD.
Summary
|
|
EudraCT number |
2007-003169-42 |
Trial protocol |
NL DE DK BE |
Global completion date |
30 Sep 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 May 2016
|
First version publication date |
10 Apr 2015
|
Other versions |
|
Summary report(s) |
1249.1 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.